Document Detail


The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models.
MedLine Citation:
PMID:  19917276     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Miltefosine is currently marketed for treatment of skin metastasis of breast cancer and leishmaniasis. The mechanism of action is not fully understood, however, miltefosine is considered to be a prototype lipid raft modulator. The compound was shown to inhibit anti-IgE induced histamine release from human skin mast cells. After topical treatment it reduced skin reaction in allergic human volunteers undergoing a skin prick test. The aim of this study was to test whether miltefosine could also modify T-cell signalling and whether the drug may be useful for the treatment of atopic dermatitis. Miltefosine (20microM) inhibited T-cell proliferation by >50% in the mixed leukocyte test. In the toluene diisocyanate induced ear swelling test, miltefosine, administered topically as 2 and 6% solution or orally, attenuated ear swelling reaching 70% of the effect of dexamethasone at 100mg/kg p.o. (P<0.01). The ear tissue content of the cytokines IL1beta, IL4 and IL6 was also reduced reaching 56% or 52% reduction of IL1beta (P<0.01) after 2% topical or 100mg/kg p.o. Miltefosine significantly attenuated the allergic sensitization in the model of ovalbumin induced delayed-type hypersensitivity in mice. In a model of toluene diisocyanate induced scratching a significant (P=0.0047) reduction of scratching from 47 to 6 bouts was achieved with 100mg/kg p.o. The data indicate that miltefosine modulates T-cell function in models for Th1 and Th2 related activity. This profile opens up the possibility for the treatment of T-cell related allergic diseases with a novel class of lipid raft modulator drugs such as miltefosine.
Authors:
Wolfgang B?umer; Piotr Wla?; Gary Jennings; Chris Rundfeldt
Related Documents :
17298426 - Chemokine receptor expression on allergen-specific t cells in asthma and allergic bronc...
19828516 - Basophils in the giant papillae of chronic allergic keratoconjunctivitis.
1443456 - Nasal memory t lymphocytes capable of producing il-4 in the allergic reaction.
3195836 - The influx of inflammatory cells into nasal washings during the late response to antige...
2378986 - Evidence that chronic lymphocytic leukemia b lymphocytes are frequently committed to pr...
18981096 - Enhanced early expansion and maturation of semi-invariant nk t cells inhibited autoimmu...
Publication Detail:
Type:  Journal Article     Date:  2009-11-14
Journal Detail:
Title:  European journal of pharmacology     Volume:  628     ISSN:  1879-0712     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-27     Completed Date:  2010-04-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  226-32     Citation Subset:  IM    
Affiliation:
Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Hannover, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Administration, Topical
Animals
Anti-Inflammatory Agents / administration & dosage,  immunology,  pharmacology,  therapeutic use
Arachidonic Acid / pharmacology
Disease Models, Animal
Ear / pathology
Female
Hypersensitivity / immunology
Immunologic Factors / administration & dosage,  immunology,  pharmacology,  therapeutic use
Inflammation / chemically induced,  drug therapy,  immunology*,  metabolism
Interleukins / metabolism
Membrane Microdomains / drug effects*
Mice
Phosphorylcholine / administration & dosage,  analogs & derivatives*,  immunology,  pharmacology,  therapeutic use
Pruritus / drug therapy,  immunology
Skin / drug effects,  immunology,  pathology*
T-Lymphocytes / immunology*
Toluene 2,4-Diisocyanate / immunology
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Immunologic Factors; 0/Interleukins; 107-73-3/Phosphorylcholine; 506-32-1/Arachidonic Acid; 58066-85-6/miltefosine; 584-84-9/Toluene 2,4-Diisocyanate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu((R))) and active metabo...
Next Document:  Anti-glycative effects of oleanolic acid and ursolic acid in kidney of diabetic mice.